Business Information
The company's principal activity is developing novel, small-molecule drug. Its business model is to develop a portfolio of drug candidates through phase ii clinical research, after which the company intends to seek commercialization partners for clinical evaluation, regulatory approval and marketing. The company's lead product research programs focus on: mast cell activation to treat immunologic diseases such as asthma/allergy and autoimmune disorders; an antiviral agent to treat hepatitis c, and ubiquitin ligases, a new class of cancer drug target. The company has begun clinical testing of its first product, for allergic rhinitis, and plans to follow this with two additional drugs in the clinic by the end of 2003. The company's approach to drug discovery is based on advanced, proprietary functional genomics techniques that allow it to directly identify targets that regulate disease pathways and are also suitable for drug modulation.
|
|
Name |
Title
|
Email
|
| James Gower | Chmn., CEO | N/A | | Ryan Maynard | CFO, VP | N/A | | Dolly Vance | Sr. VP, General Counsel, Corp. Sec. | N/A | | Donald Payan | Co - Founder, Dir., Exec. VP, Chief Scientific Officer | N/A | | Elliott Grossbard | Sr. VP - Medical Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 33,473 | (37,637) | | 2005 | 16,526 | (45,256) | | 2004 | 4,733 | (56,255)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
